Brain-computer interface developer building minimally-invasive endovascular implants
Biotech📍 Brooklyn, NYFounded 2016
Current Valuation
$1.0B
as of 2024-Q4
UNICORN
IPO Outlookprivate
Is Synchron going public?
No. Synchron has no imminent IPO plans on record. It is still private.
What is Synchron's valuation in 2026?
Synchron is valued at $1.0B as of 2024-Q4, set by its Series C ($75M, Dec 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Synchron filed an S-1?
No public S-1 is on file for Synchron.
Who are Synchron's investors?
Synchron's investors include ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, Bill Gates, Reliance Industries, NVIDIA.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Synchron's Stentrode is a stent-mounted electrode array implanted via the jugular vein, avoiding open-brain surgery. First BCI company to receive FDA Investigational Device Exemption (IDE) for human trials in the US. Has implanted devices in patients with ALS to enable computer control via thought.
Company Profile
CEO
Tom Oxley
Founded
2016
HQ
Brooklyn, NY
Employees
~70
Total Raised
$145M
Last Round
Series C — $75M (Dec 2024) · Lead: ARCH Venture Partners
IPO Status
no imminent plans
Fundraising Status
Series C · $75M · 1y 8mo ago
no imminent plansTotal raised $145M
Secondary Market
Implied price / share
$34.68
Open interest
3
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$75M
Dec 2024
ARCH Venture Partners
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
3
3 active · 3 recruiting
Focus areas
Motor Neuron Disease
ALS · Neurologic Disorder
Latest trial start
2026-05-22
Name-verified against lead sponsor "Synchron, Inc." on ClinicalTrials.gov as of 2026-08-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
9
via careers page
Product-build share
78%
engineering, research, product, design
Trajectory
steady
heavy product build — 78% of open roles are product-building functions (engineering/research/product) — 3 of 9 open roles are hardware.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Synchron MedicalSenior R & D Engineer, Mechanical/Biomedical (opens in new tab)San Diego, CA→Senior Quality Engineer-New Product Dev- CA (opens in new tab)San Diego, CA→Senior Quality Engineer-Operations-CA (opens in new tab)San Diego, CA→Electrical Engineer, ASIC Program Lead-CA (opens in new tab)San Diego, CA→Senior Engineer, Mechanical Engineering- CA (opens in new tab)San Diego, CA→
Counted from Synchron's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Neuralink · Paradromics · Onward Medical · Blackrock Neurotech
BiotechBCIMedical DeviceBezos Backed
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q4. Refreshed quarterly.